Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$17.69 -0.4%	$18.18	$16.10 ▼ $42.47	$2.22B	0.68	2.34 million shs	2.09 million shs
AXSM Axsome Therapeutics	$100.69 -2.1%	$106.75	$72.21 ▼ $139.13	$4.96B	0.48	677,890 shs	1.15 million shs
FOLD Amicus Therapeutics	$5.64 -1.6%	$6.39	$5.62 ▼ $12.65	$1.74B	0.54	3.08 million shs	17.42 million shs
MLTX MoonLake Immunotherapeutics	$43.50	$40.88	$31.42 ▼ $58.26	$2.78B	1.24	382,410 shs	240,424 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	-6.05%	-0.51%	-26.72%	-55.85%
AXSM Axsome Therapeutics	0.00%	-3.28%	-3.51%	-20.59%	+32.45%
FOLD Amicus Therapeutics	0.00%	-6.47%	-9.90%	-37.40%	-42.27%
MLTX MoonLake Immunotherapeutics	0.00%	-1.61%	+12.96%	+8.42%	+10.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.6948 of 5 stars	4.3	3.0	4.4	3.2	2.5	0.6
AXSM Axsome Therapeutics	4.6556 of 5 stars	4.5	2.0	4.5	1.4	4.2	0.6
FOLD Amicus Therapeutics	3.9636 of 5 stars	3.4	2.0	4.3	1.8	0.0	1.9
MLTX MoonLake Immunotherapeutics	1.2272 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	126.41% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	71.15% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	187.63% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	80.95% Upside

Current Analyst Ratings Breakdown

Latest APLS, AXSM, FOLD, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.85	N/A	N/A	$1.84 per share	9.61
AXSM Axsome Therapeutics	$385.69M	12.85	N/A	N/A	$1.18 per share	85.33
FOLD Amicus Therapeutics	$528.29M	3.29	N/A	N/A	$0.65 per share	8.68
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	35.71	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.12	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)

Latest APLS, AXSM, FOLD, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
AXSM Axsome Therapeutics	3.48	2.03	1.96
FOLD Amicus Therapeutics	2.02	3.34	2.47
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
AXSM Axsome Therapeutics	81.49%
FOLD Amicus Therapeutics	N/A
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.80%
AXSM Axsome Therapeutics	22.40%
FOLD Amicus Therapeutics	2.20%
MLTX MoonLake Immunotherapeutics	12.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.14 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.30 million	Optionable

APLS, AXSM, FOLD, and MLTX Headlines

Recent News About These Companies

MoonLake Immunotherapeutics (NASDAQ:MLTX) vs. DURECT (NASDAQ:DRRX) Head to Head Survey

June 15, 2025 | americanbankingnews.com

Cantor Fitzgerald Weighs in on MLTX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc.

June 11, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Buy" by Analysts

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts MLTX FY2026 Earnings

June 10, 2025 | marketbeat.com

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News

June 9, 2025 | gurufocus.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - What's Next?

June 6, 2025 | marketbeat.com

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help

June 5, 2025 | statnews.com

MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX

June 5, 2025 | nasdaq.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume Increase - Here's Why

June 4, 2025 | marketbeat.com

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

June 4, 2025 | zacks.com

Wellington Management Group LLP Lowers Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)

June 4, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

June 4, 2025 | marketbeat.com

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

June 3, 2025 | seekingalpha.com

Constellation and Meta, Merck, Snowflake: Trending Tickers

June 3, 2025 | finance.yahoo.com

Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT

June 3, 2025 | fiercebiotech.com

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

June 3, 2025 | msn.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What Happened

June 3, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Outperform Rating from Royal Bank of Canada

June 3, 2025 | marketbeat.com

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

June 3, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS, AXSM, FOLD, and MLTX Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.68 -0.01 (-0.06%)

As of 06/20/2025 06:15 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Axsome Therapeutics NASDAQ:AXSM

$100.69 -2.20 (-2.14%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.40 +4.71 (+4.68%)

As of 06/20/2025 05:12 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Amicus Therapeutics NASDAQ:FOLD

$5.64 -0.09 (-1.57%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.64 +0.00 (+0.09%)

As of 06/20/2025 07:33 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

MoonLake Immunotherapeutics NASDAQ:MLTX

$43.50 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$43.52 +0.02 (+0.05%)

As of 06/20/2025 07:25 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time